Clinical Trials Directory

Trials / Completed

CompletedNCT00748345

Pharmacokinetics of Caspofungin in Burn Patients

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
2 (actual)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Drug pharmacokinetics of antimicrobial agents is significantly altered in the burn patients. Additionally, burn patient population exhibits a wide inter- and intrapatient variation in drug handling. Several investigations carried out in burn patients treated with e.g. fluconazole showed the requirement to increase daily dose in comparison with healthy volunteers. However, no pharmacokinetic data are available of caspofungin in the burn population. The aim of this investigation is to investigate pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population.

Detailed description

The aim of this investigation is to investigate pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.). Blood samples are drawn just before administration and 0.25, 0.5,1 1.5, 3, 6, 12, 24, 48, 72, 96 and 120 hours after administration. Caspofungin plasma concentrations are measured by liquid-chromatography spectrometry mass tandem.The primary end-points are : * area under the curve of caspofungin plasma concentrations over 24 hours * mean peak level and trough concentration (24 hours after dosing) The secondary end-points are : * mean total clearance * mean distribution volume These parameters will be compared to those usually observed in non burn patients. The optimal dose in burn patients is the dose achieving an exposure similar to that in non burn patients.

Conditions

Interventions

TypeNameDescription
DRUGCaspofungin (drug)pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population

Timeline

Start date
2009-02-01
Primary completion
2010-02-01
Completion
2010-12-01
First posted
2008-09-08
Last updated
2026-03-04

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT00748345. Inclusion in this directory is not an endorsement.